严重的精神疾病和心脏保护药物处方:一般医院的定性研究
Amanda Vettini1, Gearóid K Brennan2, Stewart W Mercer3
1Centre for Population Health Sciences, Usher Institute, University of Edinburgh, Edinburgh, UK Amanda.Vettini@glasgow.ac.uk.
BJGP open
|February 14, 2024
概括
一般医生面临的重大障碍是给患有严重精神疾病 (SMI) 的患者开心脏保护药物. 系统性问题和患者的复杂性阻碍了在这个脆弱人群中有效预防心血管疾病.
科学领域:
- 一般实践一般实践
- 心血管健康 心血管健康
- 心理健康服务 心理健康服务
背景情况:
- 患有严重精神疾病 (SMI) 的患者经历过早死亡,主要是由于心血管疾病 (CVD).
- 对于SMI患者的心脏保护药物处方存在差异.
- 了解处方挑战对于改善护理公平至关重要.
研究的目的:
- 调查全科医生在给SMI患者开心脏保护药物时遇到的障碍.
- 确定影响SMI人群心血管疾病风险管理的因素.
主要方法:
- 这是一项定性研究,涉及苏格兰11个实践中的15名全科医生.
- 进行了半结构面试,并进行了主题分析.
- 该研究包括服务于贫困地区的实践,称为深端实践.
主要成果:
- 一般医生报告了许多障碍,包括资金短缺,有限的咨询时间,劳动力赤字和IT基础设施问题.
- 与患者相关的挑战包括复杂的健康和社会需求,以及优先考虑心理健康而不是身体健康.
- 职业障碍涉及整体护理偏好和对药物坚持的担忧.
- 护理的连续性被确定为心血管健康管理的关键推动因素.
结论:
- 尽管有意处方心脏保护药物,但系统,专业和患者层面的障碍阻碍了SMI患者有效降低心血管风险.
- 这些挑战在贫困地区加剧了,突出了反向护理法.
- 解决这些多方面的障碍对于改善SMI患者的健康结果至关重要.
相关概念视频
Assessment of the Cardiovascular System I: Subjective Data
339
A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
339
Drug Therapy
44
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
44
Psychosis: Goals of Pharmacotherapy
130
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
130
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
744
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
744
Pharmacovigilance
833
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
833


